An Exploratory Analysis of the Association Between Catechol-O-Methyltransferase and Response to a Randomized Open-Label Placebo Treatment for Cancer-Related Fatigue
Teri W Hoenemeyer, Navneet Kaur Baidwan, Kathryn Hall, Ted J Kaptchuk, Kevin R Fontaine, Tapan S Mehta, Teri W Hoenemeyer, Navneet Kaur Baidwan, Kathryn Hall, Ted J Kaptchuk, Kevin R Fontaine, Tapan S Mehta
Abstract
Previous studies have identified catechol-O-methyltransferase (COMT), as a key enzyme influencing sympathetic function. Although the COMT SNP rs4680 and rs4818, are well-studied, little is known about their influence on cancer-related fatigue (CrF) and placebo response. In this study, we examined whether genetic variation in COMT, at the functional SNP rs4680 and linked rs4818, influenced open-label placebo (OLP) responses found in cancer survivors reporting moderate to severe CrF. We randomized cancer survivors (N = 74) reporting moderate-to-severe CrF to receive OLP or to treatment-as-usual (TAU) and assessed if rs4680 and rs4818 were associated with changes in fatigue severity and fatigue-distressed quality of life. At the end of the initial 21 days, the treatments were crossed over and both groups were re-assessed. Participants with the rs4680 high-activity G-allele (G/G or G/A) or rs4818 C/G genotypes reported significant decreases in fatigue severity and improvements in fatigue-distressed quality of life. The COMT rs4818 findings replicated findings in a similar study of OLP in cancer fatigue. Clinical Trial Registration: www.ClinicalTrials.gov, identifier: NCT02522988.
Keywords: COMT (rs 4680); COMT rs4818 polymorphism; cancer related fatigue; non-deceptive placebo; placebo effect.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Copyright © 2021 Hoenemeyer, Baidwan, Hall, Kaptchuk, Fontaine and Mehta.
Figures
References
- American Cancer Society . Cancer Treatment and Survivorship Facts and Figures: 2014-2015. Available online at: (accessed July 31, 2018).
- Bower JE, Bak K, Berger A, Breitbard W, Escalante CP, Ganz PA, et al. . Screening, assessment, and management of fatigue in adult survivors of cancer: an American society of clinical oncology clinical practice guideline adaptation. J Clin Oncol. (2014) 32:1840–51. 10.1200/JCO.2013.53.4495
- National Comprehensive Cancer Network . Clinical Practice Guidelines in Oncology: Cancer-Related Fatigue. (2015). Available online at: (accessed July 31, 2018).
- National Cancer Institute . Fatigue PDQ Health Professional Version. Available online at: (accessed July 31, 2018).
- Brown JC, Huedo-Medina TB, Pescatello LS, Pescatello SM, Ferrer RA, Johnson BT. Efficacy of exercise interventions in modulating cancer-related fatigue among adult cancer survivors: a meta-analysis. Cancer Epidemiol Biomarkers Prev. (2011) 20:123–33. 10.1158/1055-9965.EPI-10-0988
- Cramp F, Byron-Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Datab Syst Rev. (2012) 11:CD006145. 10.1002/14651858.CD006145
- Goedendorp MM, Gielissen MF, Verhagen CA, Bleijenberg G. Psychosocial interventions for reducing fatigue during cancer treatment in adults. Cochrane Database Syst Rev. (2009) 1:CD006953. 10.1002/14651858.CD006953.pub2
- Jacobsen PB, Donovan KA, Vadaparampil ST, Small BJ. Systematic review and meta-analysis of psychological and activity-based interventions for cancer-related fatigue. Health Psychol. (2007) 26:660–7. 10.1037/0278-6133.26.6.660
- Kangas M, Bovbjerg DH, Montgomery GH. Cancer-related fatigue: a systematic and meta-analytic review of non-pharmacological therapies for cancer patients. Psychol Bull. (2008) 134:700–41. 10.1037/a0012825
- Puetz TW, Herring MP. Differential effects of exercise on cancer-related fatigue during and following treatment: a meta-analysis. Am J Prev Med. (2012) 43:e1–24. 10.1016/j.amepre.2012.04.027
- Minton O, Richardson A, Sharpe M, Hotopf M, Stone P. A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. J Natl Cancer Inst. (2008) 100:1155–66. 10.1093/jnci/djn250
- Davis JM, Bailey SP. Possible mechanisms of central nervous system fatigue during exercise. Med Sci Sport Exerc. (1997) 29:45–57. 10.1097/00005768-199701000-00008
- Fernstrom JD, Fernstrom MH. Exercise, serum free tryptophan, and central fatigue. J Nutr. (2006) 136:553S−9S.
- Newsholme EA, Blomstrand E. Branched-chain amino acids and central fatigue. J Nutr. (2006) 136(Suppl. 1):274S−6S. 10.1093/jn/136.1.274S
- Ryan JL, Carroll JK, Ryan EP, Mustian KM, Fiscella K, Morrow GR. Mechanisms of cancer-related fatigue. Oncologist. (2007) 12(Suppl. 1):22–34. 10.1634/theoncologist.12-S1-22
- Gazmararian JA, Koplan JP, Cogswell ME, Bailey CM, Davis NA, Cutler CM. Maternity experiences in a managed care organization. Health Affairs. (1997) 16:198–208. 10.1377/hlthaff.16.3.198
- Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International chronic fatigue syndrome study group. Ann Intern Med. (1994) 121:953–9. 10.7326/0003-4819-121-12-199412150-00009
- Giacalone A, Quitadamo D, Zanet E, Berretta M, Spina M, Tirelli U. Cancer-related fatigue in the elderly. Support Care Cancer. (2013) 21:2899–911. 10.1007/s00520-013-1897-1
- Castell L, Yamamoto T, Phoenix J, Newsholme E. The role of tryptophan in fatigue in different conditions of stress. Adv Exp Med Biol. (1999) 467:697–704. 10.1007/978-1-4615-4709-9_90
- Barsevick A, Frost M, Zwinderman A, Hall P, Halyard M, GENEQOL Consortium. I'm so tired: biological and genetic mechanisms of cancer-related fatigue. Qual Life Res. (2010) 19:1419–27. 10.1007/s11136-010-9757-7
- Morrow GR, Andrews PL, Hickok JT, Roscoe JA, Matteson S. Fatigue associated with cancer and its treatment. Support Care Cancer. (2002) 10:389–98. 10.1007/s005200100293
- Fagundes C, Murray D, Hwang B, Gouin J, Thayer J, Sollers JJ, et al. . Sympathetic and parasympathetic activity in cancer-related fatigue: more evidence for a physiological substrate in cancer survivors. Psychoneuroendocrinology. (2011) 36:1137–47. 10.1016/j.psyneuen.2011.02.005
- Hall KT, Kossowsky J, Oberlander TF, Kaptchuk TJ, Saul JP, Wyller VB, et al. . Genetic variation in catechol-O-methyltransferase modifies effects of clonidine treatment in chronic fatigue syndrome. Pharmacogenomics J. (2016) 16:454–60. 10.1038/tpj.2016.53
- Wyller VB, Saul JP, Amlie JP, Thaulow E. Sympathetic predominance of cardiovascular regulation during mild orthostatic stress in adolescents with chronic fatigue. Clin Physiol Funct Imaging. (2007) 27:231–8. 10.1111/j.1475-097X.2007.00743.x
- Fagermoen E, Sulheim D, Winger A, Andersen AM, Gjerstad J, Godang K, et al. . Effects of low-dose clonidine on cardiovascular and autonomic variables in adolescents with chronic fatigue: a randomized controlled trial. BMC Pediatr. (2015) 15:117. 10.1186/s12887-015-0428-2
- Wyller VB, Vitelli V, Sulheim D, Fagermoen E, Winger A, Godang K, et al. . Altered neuroendocrine control and association to clinical symptoms in adolescent chronic fatigue syndrome: a cross-sectional study. J Transl Med. (2016) 14:121. 10.1186/s12967-016-0873-1
- Sagud M, Tudor L, Uzun S, Perkovic MN, Zivkovic M, Konjevod M, et al. . Haplotypic and genotypic association of catechol-O-Methyltransferase rs4680 and rs4818 polymorphisms and treatment resistance in schizophrenia. Front Pharmacol. (2018) 9:705. 10.3389/fphar.2018.00705
- Candiotti KA, Yang Z, Buric D, Arheart K, Zhang Y, Rodriguez Y, et al. . Catechol-o-methyltransferase polymorphisms predict opioid consumption in postoperative pain. Anesth Analg. (2014) 119:1194–200. 10.1213/ANE.0000000000000411
- Hoenemeyer TW, Kaptchuk TJ, Mehta TS, Fontaine KR. Open-label placebo treatment for cancer-related fatigue: a randomized-controlled clinical trial. Sci Rep. (2018) 8:2784. 10.1038/s41598-018-20993-y
- Corbett TK, Groarke A, Devane D, Carr E, Walsh JC, McGuire BE. The effectiveness of psychological interventions for fatigue in cancer survivors: systematic review of randomised controlled trials. Syst Rev. (2019) 8:324. 10.1186/s13643-019-1230-2
- Kirsch I. Placebo effect in the treatment of depression and anxiety. Front Psychiatry. (2019) 10:407. 10.3389/fpsyt.2019.00407
- Donovan K, Jacobsen P. The fatigue symptom inventory: a systematic review of its psychometric properties. Support Care Cancer. (2010) 19:169–85. 10.1007/s00520-010-0989-4
- Donovan KA, Stein KD, Lee M, Leach CR, Illozumba O, Jacobsen PB. Systematic review of the multidimensional fatigue symptom inventory short form. Support Care Cancer. (2015) 23:191–212. 10.1007/s00520-014-2389-7
- Mione V, Canterini S, Brunamonti E, Pani P, Donno F, Fiorenza MT, et al. . Both the COMT Val158Met single-nucleotide polymorphism and sex-dependent differences influence response inhibition. Front Behav Neurosci. (2015) 9:127. 10.3389/fnbeh.2015.00127
- Zhou ES, Hall KT, Michaud AL, Blackmon JE, Partridge AH, Recklitis CJ. Open-label placebo reduces fatigue in cancer survivors: a randomized trial. Support Care Cancer. (2019) 27:2179–87. 10.1007/s00520-018-4477-6
- Stein DJ, Newman TK, Savitz J, Ramesar R. Warriors versus worriers: the role of COMT gene variants. CNS Spectr. (2006) 11:745–8. 10.1017/S1092852900014863
- Vasunilashorn SM, Ngo LH, Jones RN, Inouye SK, Hall KT, Gallagher J, et al. . The association between c-reactive protein and postoperative delirium differs by catechol-o-methyltransferase genotype. Am J Geriatr Psychiatry. (2019) 27:1–8. 10.1016/j.jagp.2018.09.007
- Wang T, Yin J, Miller AH, Xiao C. A systematic review of the association between fatigue and genetic polymorphisms. Brain Behav Immun. (2017) 62:230–44. 10.1016/j.bbi.2017.01.007
- Collado-Hidalgo, Bower JE, Ganz PA, Irwin MR, Cole SW. Cytokine gene polymorphisms and fatigue in breast cancer survivors: early findings. Brain Behav Immun. (2008) 22:1197–200. 10.1016/j.bbi.2008.05.009
- Kambur O, Männistö P. Basic aspects of catechol-O-methyltransferase and the clinical applications of its inhibitors. In: International Review of Neurobiology. Amsterdam: Academic press. (2010). p. 227–79.
- Hall KT, Lembo AJ, Kirsch I, Ziogas DC, Douaiher J, Jensen KB, et al. . Catechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome. PLoS One. (2012) 7:e48135. 10.1371/journal.pone.0048135
- Colagiuri B, Schenk LA, Kessler MD, Dorsey SG, Colloca L. The placebo effect: from concepts to genes. Neuroscience. (2015) 307:171–90. 10.1016/j.neuroscience.2015.08.017
- Hall KT, Loscalzo J, Kaptchuk TJ. Genetics and the placebo effect: the placebome. Trends Mol Med. (2015) 21:285–94. 10.1016/j.molmed.2015.02.009
- Wang RS, Hall KT, Giulianini F, Passow D, Kaptchuk TJ, Loscalzo J. Network analysis of the genomic basis of the placebo effect. JCI Insight. (2017) 2:e93911. 10.1172/jci.insight.93911
- Lin CH, Chaudhuri KR, Fan JY, Ko CI, Rizos A, Chang CW, et al. . Depression and catechol-O-methyltransferase (COMT) genetic variants are associated with pain in Parkinson's disease. Sci Rep. (2017) 7:6306. 10.1038/s41598-017-06782-z
- Fernadez de-Las-Peñas C, Ambite-Quesada S, Palacios-Ceña M, Guillem-Mesado A, Guerrero-Peral Á, Pareja JA, et al. . Catechol-O-Methyltransferase (COMT) rs4680 Val158Met polymorphism is associated with widespread pressure pain sensitivity and depression in women with chronic, but not episodic, tension-type headache. Clin J Pain. (2019) 35:345–52. 10.1097/AJP.0000000000000684
- Liu J, Wu J, Nie G, Zeng W, Zhand M, Tan L, et al. . Catechol-O-methyl transferase SNP rs4680 influence risk of mood disorder: a meta-analysis. Int J Clin Exp Med. (2016) 9:6152–65.
- Lombardi DA. The case-crossover study: a novel design in evaluating transient fatigue as a risk factor for road traffic accidents. Sleep. (2010) 33:283–4. 10.1093/sleep/33.3.283
Source: PubMed